Authors
Latest:
Opsoclonus-Myoclonus–Associated Neuroblastoma With Bone Marrow Metastases: What Would Be the Best Treatment Option?In this clinical quandary, investigators determine how to best treat patients with opsoclonus-myoclonus–associated neuroblastoma with bone marrow metastases.
Latest:
Achieving Health Equity in Lung Cancer SurgeryRian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
Latest:
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETsRead about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Latest:
Telemedicine Use in Oncology PracticesABSTRACT Telemedicine (TM) will play an increasingly significant role in practices that diagnose cancers and treat patients. Although only a small percentage of oncologists currently use TM, many more will embrace this technology in the near future. Although TM has been available for several decades, it was the coronavirus disease 2019 pandemic that highlighted how useful the concept was for connecting and communicating not only with patients who live a significant distance away from their oncologist’s brick-and-mortar office, but with those who are homebound, for whatever reason. For instance, patients who have tested positive for coronavirus but who are not significantly symptomatic can be safely treated while they remain at home. One barrier to the widespread implementation of TM was lack of compensation for the time spent communicating with patients using audio-visual technology. As of March 2020, however, CMS has mandated that TM virtual visits and face-to-face visits have financial parity. This article will explore the process of implementing TM into an oncology practice with minimal time, energy, effort, and expense, as well as the concepts and the trends behind using TM to provide care for patients with cancer.
Latest:
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural EffusionThis case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
Latest:
Looking Ahead in the Multiple Myeloma Treatment LandscapeExperts from City of Hope close out their panel on multiple myeloma management by identifying unmet needs and sharing what excites them in the future evolution of the treatment landscape.
Latest:
QOL vs Survival Should be Considered Prior to Chemo in Geriatric TNBCFindings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Exploring Novel Treatment Options in Patients With RRMMThe panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Uterine Transposition May Maintain Fertility Following Pelvic RadiotherapyUterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Future Directions in Advanced Endometrial CarcinomaClosing the discussion on advanced endometrial carcinoma, Dr David O’Malley shares his perspective on the future treatment landscape.
Latest:
Fianlimab Combo Shows Activity in Advanced Melanoma SubtypesThe safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Considerations for the Management of Oncology Patients During the COVID-19 PandemicABSTRACT Worldwide incidence and mortality due to the coronavirus disease 2019 (COVID-19) pandemic is greatest in the United States, with the initial epicenter in New York. In Nassau County, New York, where we practice, our institution has had more than 2500 cases and has discharged from the hospital more than 1000 patients. As many academic and private institutions have swiftly shifted their clinical and research priorities to address the pandemic, data are emerging regarding both the impact of malignancy on COVID-19 outcomes as well as the challenges faced in assuring that cancer care remains unimpeded. Of concern, recent studies of cancer patients primarily in China and Italy have suggested that advanced malignancy is associated with increased susceptibility to severe COVID-19 infection. At present, more than 500 clinical trials are underway investigating the pathogenesis and treatment of COVID-19, including expanded use of oncology drugs, such as small molecular inhibitors of cytokine pathways. Here, we begin by reviewing the latest understanding of COVID-19 pathophysiology and then focus our attention on the impact of this virus on hematologic and oncologic practice. Finally, we highlight ongoing investigational treatment approaches that are so relevant to the care of oncology patients during this extraordinary pandemic.
Latest:
Declan Murphy, MB, BCh, on Rate of Equivocal Findings on PSMA PET/CT in Patients With Prostate CancerMurphy discussed the secondary end point of equivocal findings on PSMA PET/CT from the proPSMA study presented at the SUO 21st Annual Meeting.
Latest:
Navigating High-Risk Disease in Multiple Myeloma: Treatment Strategies and the Role of ASCTExperts dive into the complexities of defining and treating high-risk Multiple Myeloma (MM) and discuss the role of ASCT in newly diagnosed MM and weigh the considerations for recommending transplants, including insights on the selection criteria for tandem transplantations.
Latest:
Guido Lancman, MD, on Next Steps for a Study of IVIG in Patients with Multiple Myeloma Receiving DaratumumabHypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.
